Literature DB >> 33437395

Long non-coding RNA AFAP1-AS1 promotes cell growth and inhibits apoptosis by binding to specific proteins in germinal center B-cell-like diffuse large B-cell lymphoma.

Hongyu Gao1, Ying Sun1, Jiawen Chen1, Hong Jin2, Wei Yang1.   

Abstract

Germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL) is a common subtype of lymphoma in adults. Previously, we found that actin filament-associated protein 1-antisense RNA 1 (AFAP1-AS1) is among the most overexpressed lncRNAs in GCB-DLBCL. In this study, we explored its biological functions and molecular mechanisms in the progression of GCB-DLBCL. We discovered, via bioinformatics, that patients with a high expression of AFAP1-AS1 had significantly poor disease-free survival (DFS) and overall survival (OS). Subsequent assays demonstrated that AFAP1-AS1 knockdown inhibited cell proliferation and prompted arrest of the G0/G1 cell cycle and apoptosis in GCB-DLBCL cell lines. Proteomics analysis indicated that hundreds of proteins were deregulated after AFAP1-AS1 knockdown and KEGG pathway analysis revealed that the deregulated proteins belonged to multiple signaling pathways, such as "B-cell receptor signaling pathway". Moreover, in the comprehensive identification of proteins that bind to RNA (by ChIRP-MS), several proteins associated with RNA splicing were identified (e.g., SFPQ, NONO, SRSF2, SRSF6, and KHSRP) that could specifically bind to AFAP1-AS1, which was confirmed by parallel reaction monitoring assay (PRM). Conclusively, we demonstrated that AFAP1-AS1 is a possible prognostic marker of poor outcomes in GCB-DLBCL patients and could modulate gene expression through connecting to specific proteins to practice its oncogenic role in GCB-DLBCL. AJTR
Copyright © 2020.

Entities:  

Keywords:  AFAP1-AS1; alternative splicing; apoptosis; germinal center B-cell-like diffuse large B-cell lymphoma

Year:  2020        PMID: 33437395      PMCID: PMC7791486     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  39 in total

Review 1.  Epidemiology of hematological malignancies.

Authors:  D Rodriguez-Abreu; A Bordoni; E Zucca
Journal:  Ann Oncol       Date:  2007-01       Impact factor: 32.976

Review 2.  CBP and p300: HATs for different occasions.

Authors:  Eric Kalkhoven
Journal:  Biochem Pharmacol       Date:  2004-09-15       Impact factor: 5.858

3.  Hypomethylation of noncoding DNA regions and overexpression of the long noncoding RNA, AFAP1-AS1, in Barrett's esophagus and esophageal adenocarcinoma.

Authors:  Wenjing Wu; Tushar D Bhagat; Xue Yang; Jee Hoon Song; Yulan Cheng; Rachana Agarwal; John M Abraham; Sariat Ibrahim; Matthias Bartenstein; Zulfiqar Hussain; Masako Suzuki; Yiting Yu; Wei Chen; Charis Eng; John Greally; Amit Verma; Stephen J Meltzer
Journal:  Gastroenterology       Date:  2013-01-16       Impact factor: 22.682

4.  PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.

Authors:  Matthias Pfeifer; Michael Grau; Dido Lenze; Sören-Sebastian Wenzel; Annette Wolf; Brigitte Wollert-Wulf; Kerstin Dietze; Hendrik Nogai; Benjamin Storek; Hannelore Madle; Bernd Dörken; Martin Janz; Stephan Dirnhofer; Peter Lenz; Michael Hummel; Alexandar Tzankov; Georg Lenz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-09       Impact factor: 11.205

5.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma.

Authors:  Laura Pasqualucci; David Dominguez-Sola; Annalisa Chiarenza; Giulia Fabbri; Adina Grunn; Vladimir Trifonov; Lawryn H Kasper; Stephanie Lerach; Hongyan Tang; Jing Ma; Davide Rossi; Amy Chadburn; Vundavalli V Murty; Charles G Mullighan; Gianluca Gaidano; Raul Rabadan; Paul K Brindle; Riccardo Dalla-Favera
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

6.  Retraction Note: Upregulation of the long non-coding RNA AFAP1-AS1 affects the proliferation, invasion and survival of tongue squamous cell carcinoma via the Wnt/β-catenin signaling pathway.

Authors:  Ze-You Wang; Min Hu; Min-Hui Dai; Jing Xiong; Shuai Zhang; Han-Jiang Wu; Shan-Shan Zhang; Zhao-Jian Gong
Journal:  Mol Cancer       Date:  2019-06-01       Impact factor: 27.401

7.  LncRNA AFAP1-AS1 promotes tumorigenesis and epithelial-mesenchymal transition of osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway.

Authors:  Deyao Shi; Fashuai Wu; Shidai Mu; Binwu Hu; Binlong Zhong; Feng Gao; Xiangcheng Qing; Jianxiang Liu; Zhicai Zhang; Zengwu Shao
Journal:  J Exp Clin Cancer Res       Date:  2019-08-23

8.  Transcriptome profiling of esophageal squamous cell carcinoma reveals a long noncoding RNA acting as a tumor suppressor.

Authors:  Guifeng Wei; Huaxia Luo; Yu Sun; Jiagen Li; Liqing Tian; Wei Liu; Lihui Liu; Jianjun Luo; Jie He; Runsheng Chen
Journal:  Oncotarget       Date:  2015-07-10

9.  Upregulated long non-coding RNA AFAP1-AS1 expression is associated with progression and poor prognosis of nasopharyngeal carcinoma.

Authors:  Hao Bo; Zhaojian Gong; Wenling Zhang; Xiayu Li; Yong Zeng; Qianjin Liao; Pan Chen; Lei Shi; Yu Lian; Yizhou Jing; Ke Tang; Zheng Li; Yanhong Zhou; Ming Zhou; Bo Xiang; Xiaoling Li; Jianbo Yang; Wei Xiong; Guiyuan Li; Zhaoyang Zeng
Journal:  Oncotarget       Date:  2015-08-21

10.  Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis.

Authors:  Fei Liu; Lanting Hu; Yi Pei; Ke Zheng; Wei Wang; Shenglong Li; Enduo Qiu; Guanning Shang; Jiaming Zhang; Xiaojing Zhang
Journal:  BMC Cancer       Date:  2020-03-30       Impact factor: 4.430

View more
  2 in total

Review 1.  The emerging role non-coding RNAs in B cell-related disorders.

Authors:  Soudeh Ghafouri-Fard; Tayyebeh Khoshbakht; Bashdar Mahmud Hussen; Mohammad Taheri; Elena Jamali
Journal:  Cancer Cell Int       Date:  2022-02-22       Impact factor: 5.722

2.  lncRNA GAS5, as a ceRNA, inhibits the proliferation of diffuse large B‑cell lymphoma cells by regulating the miR‑18a‑5p/RUNX1 axis.

Authors:  Yinsha Miao; Xiaodong Chen; Mengting Qin; Wen Zhou; Yang Wang; Yanhong Ji
Journal:  Int J Oncol       Date:  2021-10-26       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.